GlassScriptPhysician profile
Anthony Vito Pasquarella
NPI 1831547017
$12,326.12
in general payments reported to CMS, 2019-2025
58 companies · $3,562 in 2025
The $3,562 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $95.00 · 2021: $849 · 2022: $1,776 · 2023: $2,422 · 2024: $3,385 · 2025: $3,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,358 · Long Term Medical Supply Or Device Loan: $1,115 · Consulting Fee: $880 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,358.21 |
| Long Term Medical Supply Or Device Loan | $1,114.55 |
| Consulting Fee | $880.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,406.51 | 2022-2024 | |
| Janssen Biotech, INC. | $1,363.89 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $773.37 | 2022-2025 | Opdivo, Reblozyl |
| Seagen INC. | $712.18 | 2021-2023 | Adcetris, Tukysa |
| Abbvie INC. | $684.06 | 2021-2025 | |
| Genentech USA, INC. | $599.43 | 2019-2025 | Lunsumio, Tecentriq, Polivy |
| Daiichi Sankyo INC. | $513.29 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Celgene Corporation | $498.01 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $494.62 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $421.91 | 2020-2025 | Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $349.83 | 2021-2022 | |
| Genmab U.S., INC. | $277.87 | 2023-2025 | Tivdak, Epkinly |
| Glaxosmithkline, LLC. | $243.28 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Array Biopharma INC | $232.25 | 2023-2025 | Mektovi, Lorbrena, Braftovi |
| Genzyme Corporation | $217.90 | 2021-2023 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $206.89 | 2022-2024 | Ayvakit |
| Eisai INC. | $183.81 | 2023-2025 | |
| Lilly USA, LLC | $178.49 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $175.25 | 2022-2025 | Keytruda |
| Amgen INC. | $175.06 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Intuitive Surgical, INC. | $170.31 | 2024-2025 | |
| Emd Serono, INC. | $167.42 | 2022-2025 | Bavencio, Tepmetko |
| Springworks Therapeutics, INC. | $167.14 | 2024-2025 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $161.39 | 2023-2025 | Zepzelca |
| Galvanize Therapeutics, INC | $151.88 | 2025 | Aliya System |
| Ipsen Biopharmaceuticals, INC | $140.21 | 2022-2025 | Onivyde, Somatuline Depot |
| Penumbra, INC. | $131.66 | 2022 | |
| Gilead Sciences, INC. | $124.39 | 2022-2025 | Trodelvy |
| Incyte Corporation | $105.34 | 2022-2025 | Pemazyre, Monjuvi, Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $98.73 | 2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $89.20 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Mirati Therapeutics, INC. | $87.21 | 2023-2024 | Krazati |
| Exelixis INC. | $76.99 | 2023-2025 | Cabometyx |
| Beone Medicines USA, INC. | $76.82 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $70.02 | 2023-2025 | |
| Astellas Pharma US INC | $62.89 | 2022-2023 | Padcev |
| Adaptive Biotechnologies Corporation | $60.28 | 2022-2023 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $57.09 | 2022-2023 | |
| Kite Pharma, INC. | $54.79 | 2025 | Yescarta |
| Adc Therapeutics America, INC. | $48.95 | 2023 | |
| Beigene USA, INC. | $46.42 | 2024 | Tevimbra, Brukinsa |
| Agios Pharmaceuticals, INC. | $42.75 | 2022-2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $38.03 | 2022 | |
| Menarini Silicon Biosystems, INC. | $34.28 | 2024 | |
| Karyopharm Therapeutics INC. | $33.68 | 2024-2025 | Xpovio |
| Sobi, INC | $32.48 | 2022-2024 | |
| Geron Corporation | $29.85 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $29.66 | 2023-2025 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $28.88 | 2025 | Libtayo |
| Sumitomo Pharma America, INC. | $26.14 | 2025 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $23.56 | 2025 | Danziten |
| Servier Pharmaceuticals LLC | $22.89 | 2025 | |
| Caris Mpi, INC. | $22.73 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $22.15 | 2022 | |
| Boston Scientific Corporation | $21.60 | 2024 | |
| Morphosys, US INC. | $21.15 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.64 | 2025 | Alymsys |
| Fennec Pharmaceuticals, INC. | $19.62 | 2025 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Pasquarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.